Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

- Stockler, Martin R., Harvey, Vernon J., Gainford, M. Corona, Fong, Akiko, Paksec, Lisa, Sourjina, Tatiana, Zannino, Diana, Gebski, Val, Simes, R. John, Forbes, John F., Coates, Alan S., Francis, Prudence A., Byrne, Michael J., Ackland, Stephen P., Fitzharris, Bernie, Van Hazel , Guy, Wilcken, Nicholas R. C., Grimison, Peter S., Nowak, Anna K.

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

- Fernández-Cuesta, Lynnette, Oakman, Catherine, Larsimont, Denis, Francis, Prudence A., Crown, John, Piccart-Gebhart, Martine, Viale, Giuseppe, Leo, Angelo Di, Olivier, Magali, Falagan-Lotsch, Patricia, Smoth, Ke-seay, Quinaux, Emmanuel, Buyse, Marc, Dolci, M. Stella, Azambuja, Evandro De, Hainaut, Pierre, Dell'Orto, Patrizia

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials

- Regan, Meredith M., Pagani, Olivia, Colleoni, Marco, Gelber, Richard D., Francis, Prudence A., International Breast Cancer Study Group (IBCSG),, SOFT Investigators,, TEXT Investigators,, Fleming, Gini F., Walley, Barbara A., Price, Karen N., Rabaglio, Manuela, Maibach, Rudolf, Ruepp, Barbara, Coates, Alan S., Goldhirsch, Aron

Adjuvant ovarian suppression in premenopausal breast cancer

- Francis, Prudence A., Regan, Meredith M., Fleming, Gini F.

Adjuvant ovarian suppression in premenopausal breast cancer

- Francis, Prudence A., Regan, Meredith M., Martino, Silvana, Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Coleman, Robert, Kerbrat, Pierre, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Rabaglio-Poretti, Manuela, Fleming, Gini F., Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Colleoni, Marco, Viale, Giuseppe, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Lang, István Láng, Ciruelos, Eva, Bellet, Meritxell, Bonnefoi, Hervé R., Climent, Miguel A., Da Prada, Gian Antonio, Burstein, Harold J.

Final 10-year results of the Breast International Group 2–98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer

- Sonnenblick, Amir, Francis, Prudence A., Lluch, Ana, Gnant, Michael, Goldhirsch, Aron, Di Leo, Angelo, Barnadas, Agusti, Cortes-Funes, Hernan, Piccart, Martine, Crown, John, Azim Jr, Hatem A., de Azambuja, Evandro, Nordenskjold, Bo, Gutierez, Jorge, Quinaux, Emmanuel, Mastropasqua, Mauro G., Ameye, Lieveke, Anderson, Michael

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

- Moore, Halle C. F., Unger, Joseph M., Partridge, Ann H., Dakhil, Shaker R., Garcia, Agustin A., Gralow, Julie, Lombard, Janine M., Forbes, John F., Martino, Silvana, Barlow, William E., Fabian, Carol J., Minasian, Lori, Phillips, Kelly-Anne, Meyskens, Frank L., Gelber, Richard D., Hortobagyi, Gabriel N., Albain, Kathy S., Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A., Goldstein, Lori J., Gomez, Henry L., Vallejos, Carlos S.

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

- Moore, Halle C. F., Unger, Joseph M., Partridge, Anne H., Dakhil, Shaker R., Garcia, Agustin A., Gralow, Julie, Lombard, Janine M, Forbe, John F., Martino, Silvana, Barlow, William E., Fabian, Carol J., Minasian, Lori, Phillips, Kelly-Anne, Meyskens, Frank L. Jr, Gelber, Richard D., Hortobagyi, Gabriel N, Albain, Kathy S., Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A., Goldstein, Lori J., Gomez, Henry L., Vallejos, Carlos S.

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

- Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

- Regan, Meredith M., Pagani, Olivia, Villani, Laura, Pizzolitto, Stefano, Öhlschlegel, Christian, Sessa, Fausto, Peg Cámara, Vicente, Rodríguez Peralto, José Luis, MacGrogan, Gaëtan, Colleoni, Marco, Goldhirsch, Aron, Price, Karen N., Francis, Prudence A., Coates, Alan S., Gelber, Richard D., Viale, Giuseppe, Fleming, Gini F., Walley, Barbara A., Kammler, Roswitha, Dell'Orto, Patrizia, Russo, Leila, Szőke, János, Doimi, Franco

Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials

- Regan, Meredith M., Francis, Prudence A., Pinotti, Graziella, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

- Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil

Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

- Ribi, Karin, Luo, Weixiu, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Bernhard, Jürg, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Merideth M., Fleming, Gini F., Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena

Are SOFT and TEXT results practice changing and how?

- Pagani, Olivia, Regan, Meredith M., Francis, Prudence A.

Supportive care of women with breast cancer: key concerns and practical solution

- Zdenkowski, Nicholas, Tesson, Stephanie, Lombard, Janine, Lovell, Melanie, Hayes, Sandra, Francis, Prudence A., Dhillon, Haryana M., Boyle, Frances M.

The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program "CASCADE"

- Savas, Peter, Teo, Zhi Ling, Kanu, Nnennaya, Dietzen, Michelle, Rowan, Andrew, Kschischo, Maik, Fox, Stephen, Bowtell, David D., Dawson, Sarah-Jane, Speed, Terence P., Swanton, Charles, Loi, Sherene, Lefevre, Christophe, Flensburg, Christoffer, Caramia, Franco, Alsop, Kathryn, Mansour, Mariam, Francis, Prudence A., Thorne, Heather A., Silva, Maria Joao

Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials

- Fleming, Gini F., Saha, Poornima, Burstein, Harold J., Parmar, Vani, Torres, Roberto, Stewart, Josephine, Bellet, Meritxell, Perello, Antonia, Dane, Faysal, Moreira, Antonio, Vorobiof, Daniel, Nottage, Michelle, Regan, Meredith M., Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Colleoni, Marco, Pagani, Olivia, Francis, Prudence A., Walley, Barbara A., Ribi, Karin, Bernhard, Jurg, Luo, Weixiu, Gomez, Henry L.

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial

- Sonnenblick, Amir, Salgado, Roberto, Crown, John, Viale, Giuseppe, Daly, Laura, Javdan, Bahar, Fujisawa, Sho, de Azambuja, Evandro, Lieveke, Ameye, Piccart, Martine, Bromberg, Jacqueline, Sotirou, Christos, Brohee, Sylvain, Zahavi, Tamar, Peretz, Tamar, van den Eynden, Gert, Rouas, Ghizlaine, Salmon, Asher, Francis, Prudence A., Di Leo, Angelo

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial

- Sonnenblick, Amir, Salgado, Roberto, Crown, John, Viale, Giuseppe, Daly, Laura, Javdan, Bahar, Fujisawa, Sho, de Azambuja, Evandro, Lieveke, Ameye, Piccart, Martine, Bromberg, Jacqueline, Sotirou, Christos, Brohee, Sylvain, Zahavi, Tamar, Peretz, Tamar, van den Eynden, Gert, Rouas, Ghizlaine, Salmon, Asher, Francis, Prudence A., Di Leo, Angelo

Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial

- Zeidan, Youssef H., Habib, Joyce G., Ameye, Lieveke, Paesmans, Marianne, de Azambuja, Evandro, Gelber, Richard D., Campbell, Ian, Nordenskjöld, Bo, Gutiérez, Jorge, Anderson, Michael, Lluch, Ana, Gnant, Michael, Goldhirsch, Aron, Di Leo, Angelo, Joseph, David J., Crown, John, Piccart-Gebhart, Martine, Francis, Prudence A.